Clinical Trial

Romiplostim N01 for Chemotherapy-induced Thrombocytopenia

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To evaluate the efficacy and safety of Romiplostim N01 to treat chemotherapy-induced thrombocytopenia in tumors
Trial Details
NCT Number NCT07063225
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Collaborators: Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University Second Hospital, Tianjin Third Central Hospital, Tianjin People's Hospital, Henan Cancer Hospital, The Second Affiliated Hospital of Kunming Medical University
Conditions Chemotherapy-induced Thrombocytopenia, Romiplostim N01
Enrollment 50 participants
Start Date 2025-08
Primary Completion 2026-08 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2025-07-14